RBC Capital raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $70 and keeps an Outperform rating on the shares. The firm’s discussion with a key opinion leader over the recent Phase 3 data for olezarsen in severe hypertriglyceridemia saw the cardiologist offer an enthusiastic take as this is the very first agent to show a benefit in acute pancreatitis in a prospective randomized clinical trial, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals’ Olezarsen Shows Strong Potential in Billion-Dollar Market, Earning Buy Rating from Analyst
- Why Did IONIS Stock (IONS) Surge to a Four-Year High?
- Cautious Optimism for Ionis Pharmaceuticals Amid Promising Olezarsen Trial Results and Pending Regulatory Hurdles
- Ionis Pharmaceuticals: Balancing Promising Trial Results with Market Uncertainties
- Ionis Pharmaceuticals price target raised to $84 from $69 at Citi